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Abstract
Aims: Defining responders to glucose lowering therapy can be important for both clinical care and for the development of a
stratified approach to diabetes management. Response is commonly defined by either HbA1c change after treatment or
whether a target HbA1c is achieved. We aimed to determine the extent to which the individuals identified as responders
and non-responders to glucose lowering therapy, and their characteristics, depend on the response definition chosen.
Methods: We prospectively studied 230 participants commencing GLP-1 agonist therapy. We assessed participant
characteristics at baseline and repeated HbA1c after 3 months treatment. We defined responders (best quartile of response)
based on HbA1c change or HbA1c achieved. We assessed the extent to which these methods identified the same
individuals and how this affected the baseline characteristics associated with treatment response.
Results: Different definitions of response identified different participants. Only 39% of responders by one definition were
also good responders by the other. Characteristics associated with good response depend on the response definition
chosen: good response by HbA1c achieved was associated with low baseline HbA1c (p,0.001), high C-peptide (p,0.001)
and shorter diabetes duration (p = 0.01) whereas response defined by HbA1c change was associated with high HbA1c (p,
0.001) only. We describe a simple novel method of defining treatment response based on a combination of HbA1c change
and HbA1c achieved that defines response groups with similar baseline glycaemia.
Conclusions: The outcome of studies aiming to identify predictors of treatment response to glucose lowering therapy may
depend on how response is defined. Alternative definitions of response should be considered which minimise influence of
baseline glycaemia.
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Introduction
Being able to identify patients who respond particularly well or
poorly to a therapy is important for both the study and application
of a stratified (personalised) approach to the management of
diabetes. Studies aiming to determine predictors and mechanisms
of altered treatment response to a therapy may select patients with
extremes of response for intensive phenotyping to maximise power
(e.g. DIRECT study, www.direct-diabetes.org), or categorise
response as part of their analysis. In clinical care identifying when
a therapy has been ineffective and can be stopped may benefit
both the patient (e.g. avoiding side effects from ineffective therapy)
and care provider (reduced cost); this approach has been
incorporated into clinical guidance in the UK advising discontin-
uation of many more expensive glucose lowering treatments if
response criteria are not achieved [1].
Response to glucose lowering therapy is conventionally defined
in one of two ways, the absolute change in HbA1c after treatment
or whether a target HbA1c is achieved. Existing studies aiming to
identify clinical and biomarker predictors of glycaemic response
have not used a consistent approach. How these methods differ in
both the individuals they identify and their associated character-
istics is unclear and has not been previously explored.
We aimed to determine the extent to which the individuals
identified as markedly good responders to glucose lowering
therapy, and their characteristics, depend on the response
definition chosen. We describe a simple alternative method of
defining treatment response based on a combination of HbA1c
change and HbA1c achieved that may have advantages over
existing definitions when studying treatment response in diabetes.
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Methods
Study population
We prospectively studied 230 non-insulin treated participants
with HbA1c $58 mmol/mol (7.5%) commencing GLP-1A
therapy as part of their usual diabetes care recruited to Predicting
Response to Incretin Based Agents (PRIBA) study (http://
clinicaltrials.gov/show/NCT01503112). We measured HbA1c at
baseline and 3 months (10–14 weeks) and assessed the following
baseline clinical characteristics: HbA1c, BMI, duration of diabetes,
age of diabetes diagnosis, glucose, C-peptide, triglycerides,
creatinine. Blood tests were performed fasting.
To avoid confounding by co-treatment change and adherence
we limited our analysis to the 169 subjects who remained on
treatment at 3 months, had no other glucose lowering treatment
increased or stopped and had .80% self-reported adherence over
the 2 weeks prior to HbA1c assessment.
Conventional response definitions
To assess whether conventional definitions of response (based
on absolute change in HbA1c or HbA1c achieved on therapy)
identified similar individuals and associated characteristics we
defined good response to GLP-1A therapy (‘responders’) as
follows:
1. HbA1c change (from baseline to 3 months),230 mmol/mol
(22.7%) (n = 38)
2. HbA1c achieved (HbA1c at 3 months on therapy) ,56 mmol/
mol (7.3%) (n = 38)
Definitions were chosen based on the quartile of best responders
for each method, using the closest thresholds which allowed equal
numbers of responders. ‘Non responders’ were defined as those
not achieving these criteria within each category. We assessed
agreement in classification of responders between different
response definitions by calculating percentage agreement and
Kappa statistic and assessed differences in baseline characteristics
using Mann-Whitney U (continuous variables) or Chi Squared
(dichotomous variables).
Novel response definitions
We developed a novel alternative method to define good
responders to therapy, combining HbA1c achieved and HbA1c
change using cut-offs based on the same centile so that only those
meeting both criteria are designated responders. For comparison
to the above methods the following definition was chosen to give
38 responders again (equating to the 41st centile of response for
each definition):
HbA1c change,221 mmol/mol (21.9%)
AND
HbA1c achieved ,62 mmol/mol (7.8%)
We also defined response groups using HbA1c change, adjusted
for baseline, using linear regression, with responders defined as the
38 participants with the greatest baseline adjusted HbA1c change
(HbA1c change unstandardised linear regression residual # 2
9.7 mmol/mol).
We examined the characteristics of responders and ‘non-
responders’ (remaining participants) for both methods and assessed
the extent to which these two methods identify the same
responders and associated characteristics.
Statistical analysis
All statistical analysis was performed using PASW Statistics for
Windows, Version 18.0. Chicago: SPSS Inc.
Laboratory analysis
HbA1c, creatinine, triglycerides and glucose were measured in
recruitment centres’ local laboratories (all CPA accredited NHS
blood science laboratories). HbA1c measurement was standardised
to the IFCC reference method procedure, all repeated measure-
ments within the same individual were analysed within the same
laboratory. C-peptide was measured in the Biochemistry Depart-
Table 1. characteristics of included participants at study baseline.
Baseline characteristic Median (IQR)
HbA1c (mmol/mol ) 85 (73–98)
HbA1c (%) 9.9 (8.8–11.1)
% male 52
Age (years) 54 (47–60)
Age at diabetes diagnosis (years) 46 (40–52)
Diabetes duration (years) 6 (3–10)
BMI (kg/m2) 40.0 (35.5–44.7)
Creatinine (mmol/L) 70 (56–84)
doi:10.1371/journal.pone.0111235.t001
Figure 1. Different methods of defining good responders to
glucose lowering therapy identify different individuals. Re-
sponse definitions based on the top quartile of response for each
method to give equal numbers of responders, n = 169.
doi:10.1371/journal.pone.0111235.g001
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ment at the Royal Devon and Exeter Hospital, Exeter, UK, using
the routine automated E170 immuno-analyser from Roche
Diagnostics (Manheim, Germany).
Ethical approval
The study was approved by the South West Research Ethics
Committee (UK). Written informed consent was obtained from all
participants.
Results
Participant baseline characteristics
Baseline characteristics of participants are shown in Table 1.
Conventional definitions of response identify different
individuals as treatment responders
Agreement between the two conventional definitions of
response was poor (Kappa statistic 0.22; 0= no agreement,
1 = perfect agreement [2]). Only 15 (39%) of responders by one
definition (Hba1c achieved or HbA1c change) were also respond-
ers using the alternative definition of good response (Figure 1).
Those identified as good responders using different
definitions have very different baseline HbA1c and
associated characteristics
The characteristics of responders by both conventional defini-
tions are shown in Table 2. Using a response definition based on
absolute change predominantly identifies those with high baseline
HbA1c whereas using a definition based on HbA1c achieved will
select those with a low baseline (median baseline HbA1c 101 vs
74 mmol/mol (11.4 vs 8.9%), p,0.001). Both duration of diabetes
and fasting C-peptide are significantly different in responders
selected by the two definitions, these are variables that are
correlated with baseline HbA1c (duration of diabetes Spearmans’s
r = 0.19, p = 0.01, C-peptide r =20.30, p = 0.001).
Apparent predictors of response will differ depending on
response definition chosen
Where treatment response is based on HbA1c achieved, low
HbA1c and fasting glucose, high C-peptide and shorter duration
of diabetes are associated with good glycaemic response to
therapy. However when using HbA1c change to define response,
the trend for these variables is in the opposite direction (higher
HbA1c and glucose, lower C-peptide and longer diabetes duration
in responders) (Figure 2, glucose not shown). Other baseline
variables are not associated with response group using either
definition (p.0.09 for all, Table S1).
A novel combination of HbA1c change and HbA1c
achieved may be used to define response groups which
do not differ by baseline HbA1c
By combining both conventional outcomes into a single
definition, response groups can be created which do not differ
by baseline (see methods). The best 38 responders using this
method have similar baseline HbA1c to non-responders (median
86.0 vs 84.0 mmol/mol (10.0 vs 9.8%) responders/non respond-
ers, p = 0.60, Figure 3). This is consistent across a range of
responses; for example when comparing the best 10%, 30% and
60% responders defined using this method with the corresponding
‘non responders’ (remaining participants), baseline HbA1cs do not
differ (#2 mmol/mol (0.2%) difference in median HbA1c and p.
0.63 for all). Responders defined this way differ from ‘non-
responders’ only by C-peptide (Figure 3) (median C-peptide
1.72 vs 1.40 nmol/L responders vs non responders, p = 0.002, p
for other baseline variables .0.1 for all).
This combined outcome method identifies similar
individuals and associated characteristics to response
groups defined by baseline adjusted HbA1c change
Defining response using linear regression baseline adjusted
HbA1c change identifies predominantly the same individuals as
the above ‘combined outcome’ method (74% responder agree-
ment, kappa statistic 0.66 (‘substantial agreement’), Figure S1).
Characteristics of responders and non responders defined using
this method are also similar (Figure 3): median baseline HbA1c
84.0 vs 85.9 mmol/mol (9.8 vs 10.0%) responders vs non
responders, p = 0.72, median C-peptide 1.80 vs 1.44 nmol/L,
p = 0.01, p.0.3 for other baseline characteristics). Agreement
between regression residuals and the combined method is high
across a range of response (best 10% responders agreement 73%,
best 50% responders agreement 88%).
Discussion
This study demonstrates that defining responders to glucose
lowering therapy by HbA1c change or HbA1c achieved will
Table 2. baseline characteristics of responders to GLP-1A therapy defined by HbA1c achieved or HbA1c change.
Responder HbA1c achieved (n =38) Responder hbA1c change (n =38) p
HbA1c (mmol/mol) 74 (66–84) 101 (86–112) ,0.001
HbA1c (%) 8.9 (8.2–9.8) 11.4 (10.0–12.4) ,0.001
Fasting glucose (nmol/l) 10.6 (8.9–12.4) 14.0 (11.4–16.3) ,0.001
% male 40% 50% 0.35
Age of diagnosis (years) 50 (38–55) 47 (40–51) 0.12
Duration diabetes (years) 5 (2–7.25) 7(4–12) 0.04
BMI (kg/m2) 41 (35–46) 40 (35–43) 0.30
Creatinine (mmol/L) 74 (60–91) 67 (55–86) 0.23
Triglycerides (mmol/L) 2.3 (1.7–3.1) 2.0 (1.5–2.6) 0.36
Fasting C-peptide (nmol/L) 1.85 (1.55–2.36) 1.28 (1.17–2.14) 0.002
Median (IQR) or %.
doi:10.1371/journal.pone.0111235.t002
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identify different individuals, with different baseline glycaemia and
associated characteristics. We suggest a simple practical alternative
combining HbA1c change and HbA1c achieved that may be used
to identify response groups that are independent of baseline
HbA1c.
In our study fewer than 40% of the top quartile of responders by
one definition of glycaemic response were also responders by the
alternative definition. This means studies categorising response to
treatment may compare very different response groups should they
choose alternate definitions of glycaemic response. Baseline
HbA1c, a major source of potential confounding, is markedly
different in responders defined by different definitions. This is
consistent with previous research that has shown that baseline
HbA1c strongly influences response to glucose lowering therapies,
with high baseline associated with greater HbA1c fall but less
likelihood of achieving glycaemic targets [3–5]. Many studies
aiming to identify predictors of response do not adjust for baseline
glycaemia; this may contribute to marked variation in the findings
of these studies, for example both low and high diabetes duration
Figure 2. Comparison of baseline HbA1c (a), diabetes duration
(b) and C-peptide (c) in ‘responders’ and ‘non-responders’ to
GLP-1A defined by HbA1c achieved or HbA1c change.
Responders n = 38, non responders n = 131.
doi:10.1371/journal.pone.0111235.g002
Figure 3. Comparison of baseline HbA1c (a), diabetes duration
(b) and C-peptide (c) in ‘responders’ and ‘non responders’ to
GLP-1A defined by combined outcome or baseline adjusted
HbA1c change (regression residuals). Responders n = 38, non
responders n= 131.
doi:10.1371/journal.pone.0111235.g003
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has been reported to be associated with good response to GLP-1
agonist therapy [6–8], while others find no association [9,10].
Our findings are also important in defining response in clinical
care. Almost all participants (89%) with baseline HbA1c $
90 mmol/mol (10.4%) in this study achieved an HbA1c fall of $
11 mmol/mol (1%), a criteria for continuing therapy beyond 6
months in the UK [1]), but few (15%) with this baseline HbA1c
will achieve an HbA1c under 58 mmol/mol (7.5%), the target for
glycaemic control set by the same organisation. The converse is
true for those with low baseline glycaemia.
Failure to compare patients with similar baseline HbA1c in
studies of treatment stratification may lead to the finding of
associations between a variable and treatment response that are in
fact simply due to an association between the ‘predictive variable’
and baseline glycaemia. This will result in opposite directions of
effect if response is defined by target HbA1c achieved rather than
absolute HbA1c change. Where a baseline characteristic is a true
predictor of response but has the opposite relationships with
baseline HbA1c the association with treatment response may be
missed due to negative confounding. This is seen with C-peptide in
our study, which is more strongly associated with response when
comparing participants with similar baseline HbA1c. While it is
possible to adjust results for baseline HbA1c when comparing
‘responders’ and ‘non responders’ to glucose lowering therapy, this
has the potential to increase error [11–13]. When recruiting
extremes of response, which will have greater power for
physiological studies, it is preferable to compare participants with
similar baseline glycaemia.
We have demonstrated a very simple and practical way to
define response groups to glucose lowering therapy that do not
differ on baseline HbA1c, by combining HbA1c change and
HbA1c achieved. This method identifies similar participants and
characteristics to using response groups based on HbA1c adjusted
response (regression residuals). However unlike regression this
method can be used to create clear clinical criteria and a
mathematical calculation is not needed to define the responder
group for each participant. This is a major advantage for studies
recruiting participants into response groups for phenotyping. This
method can also be used as a non-parametric method for the
examination of existing datasets, which could have potential
advantages where regression assumptions are not met.
While this study is limited to one glucose lowering treatment
class it is likely our findings will apply to all other glucose lowering
medicines; baseline HbA1c is associated with response to all
glucose lowering interventions including placebo [3,4,14]. This
method could also be applied to treatment stratification in other
conditions where baseline may influence apparent treatment
response, such as the treatment of hyperlipidaemia or hyperten-
sion [15,16]. For reasons of simplicity we have defined ‘non
responders’ to therapy in this article as those not meeting criteria
for the responder group. However equal comparison groups with
poor response can be defined by again specifying a combined
threshold, for example failure to achieve the 60th centile of HbA1c
change (216 mmol/mol) and HbA1c achieved (69 mmol/mol)
will define a comparison group of 38 non responders in this
cohort.
A potential disadvantage of this method is that in studies
including a wide range of baseline HbA1c it may preferentially
select those with average baseline HbA1c as responders: a
participant with a very high baseline will be unlikely to achieve
a low on treatment HbA1c, a participant with a low baseline may
be unlikely to have a large HbA1c fall. There may be advantages
to restricting phenotyping to individuals with similar baseline
glycaemia when studying physiology.
A potential limitation of this study is that differences in baseline
HbA1c observed between different response groups in this study
may have been exaggerated by the study design. We have
excluded participants with other treatment change from this
analysis as it is not possible to know what the response to GLP-1
therapy would have been had other therapy remained stable.
Those with low baseline glycaemia and good response may have
been preferentially excluded as they will be more likely to have
hypoglycaemia and stop an adjacent therapy than those with high
baseline. However this appears to have little effect: including
participants who have reduced concurrent therapies does not
substantially change the association between baseline HbA1c and
glycaemic response (Table S2). Repeating our analysis including
those who discontinued other therapy does not substantially
change our results. Although this study suggests C-peptide but not
other examined participant characteristics are associated with
glycaemia response to GLP-1 therapy these results are based on a
small cohort examining extremes of response over a short (3
month) timescale to address a methodological question, further
research will be needed to determine if these associations are of
relevance to clinical practice.
In summary our study demonstrates that the outcome of studies
aiming to identify predictors of glycaemic response to glucose
lowering therapy may depend on how treatment response is
defined. Studies defining groups of responders or non responders
to glucose lowering therapy should use alternative definitions of
response which minimise the influence of baseline HbA1c.
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